ALNY FY 2012 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M-19.4% YoY

Gross Profit

$67M100.0% margin

Operating Income

-$129M-194.0% margin

Net Income

-$106M-158.9% margin

EPS (Diluted)

$-2.11

Cash Flow

Operating Cash Flow

-$116M

Free Cash Flow

-$124M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$288M

Total Liabilities

$153M

Stockholders' Equity

$134M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$83M	-19.4%
Gross Profit	$67M	$83M	-19.4%
Operating Income	-$129M	-$55M	-136.2%
Net Income	-$106M	-$58M	-83.9%